Dr. Or joined Enanta in November 1999 and led its preclinical and early clinical development efforts, including the team responsible for achieving all milestones in the collaboration with AbbVie to develop hepatitis C treatments. Dr. Or and his team discovered glecaprevir, the protease inhibitor in AbbVie’s successful combination treatment for hepatitis C virus currently marketed as MAVYRET®. He is leading Enanta’s ongoing research on antivirals for hepatitis B virus, respiratory syncytial virus, human metapneumovirus and SARS-CoV-2, as well as the non-viral liver disease nonalcoholic steatohepatitis. Dr. Or’s team also worked on the earlier protease inhibitor in AbbVie’s VIEKIRA PAK® treatment for hepatitis C virus, and previously developed antibacterials for methicillin-resistant staphylococcus aureus (MRSA). Further, Dr. Or has managed Enanta’s research and development collaborations with Shionogi, Abbvie and Novartis.

Prior to Enanta, Dr. Or was a senior project leader and research fellow of antibacterial research at Abbott Laboratories from 1985 to 1999. Prior to Abbott, he was a member of the cardiovascular drug discovery team at Schering-Plough.

Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University. He has co-authored more than 100 publications and is listed as a co-inventor on over 260 filed U.S. patent applications.